The Queensland Government State Development and Infrastructure Department, in partnership with Brandon Capital  presents Dr Ian Holmes and Dr Melissa Byrne for Seminar 2 of 2024 TACSG program.

Join Ian and Melissa in this session, where they will share their expertise on small molecule drug discovery and considerations in preclinical development.

Ian will present an overview with personal experiences and anecdotes in small molecule drug discovery, including formal and informal phases and stages based on his pharmaceutical experience. 

Ian has a PhD in Synthetic Organic Chemistry from Nottingham University and is a co-founder of MycRx and Foray Therapeutics. As Brandon Capital's resident chemist, Ian advises Azura Ophthalmics, Axelia Oncology, Certa Therapeutics, Ena Respiratory, OccuRx and Que Oncology. Ian was previously Head of Chemistry for the Cancer CRC and has spent over 10 years as a medicinal chemist at GSK and AstraZeneca.

Dr Melissa Byrne has spent more than 15 years in the life sciences industry, with her expertise and experience spanning cardiovascular physiology, medical research, research translation, and commercialisation. She will share her understanding of the key elements required for a successful development and commercialisation program with emphasis on the importance of Target Product Profile.

Melissa has a PhD in Cardiovascular Physiology from Monash University and completed a Post Doc at Johns Hopkins Medicine, Baltimore. She has both academic and commercial experience and, prior to her position at Brandon, has held roles for both Research & Development and Clinical Operations for a number of biotech start up companies.

21st March 2024

10am-12pm

Translational Research Institute Auditorium, Translational Research Institute, 

37 Kent Street, Woolloongabba, QLD, 4106

Light lunch to follow. All welcome, please REGISTER below.